A developed determination of midazolam and 1′-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: Application of human pharmacokinetic study for measurement of CYP3A activity

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 847, Issue 2, 2007, Pages 275-281

  Shimizu, Mikiko ^a   Uno, Tsukasa ^a   Tamura, Hiro omi ^b   Kanazawa, Hideko ^b   Murakami, Isao ^b   Sugawara, Kazunobu ^c   Tateishi, Tomonori ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c AOMORI UNIVERSITY   (Japan)

Author keywords

1 Hydroxymidazolam; CYP3A; LC MS; Midazolam

Indexed keywords

DRUG INFUSION; ELECTRIC POTENTIAL; IONIZATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACOKINETICS; PHASE SEPARATION;

1PRIME-HYDROXYMIDAZOLAM; CYP3A; LC-MS; MIDAZOLAM;

DRUG DOSAGE;

ALPHA HYDROXYMIDAZOLAM; AMMONIUM ACETATE; CHLOROFORM; CYTOCHROME P450 3A; DIAZEPAM; HEXANE; METHANOL; MIDAZOLAM;

ADULT; ALKALINIZATION; ARTICLE; CHROMATOGRAPHY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTRIC POTENTIAL; EXTRACTION; FEMALE; FLOW RATE; HUMAN; HUMAN EXPERIMENT; IONIZATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; SAMPLING; SENSITIVITY ANALYSIS; STANDARD; TEMPERATURE;

ADULT; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDAZOLAM; MOLECULAR STRUCTURE; REPRODUCIBILITY OF RESULTS;

EID: 33847331529     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2006.10.018     Document Type: Article

References (33)

1. Rogers J.F., Nafziger A.N., and Bertino Jr. J.S. Am. J. Med. 113 (2002) 746
2. Ozdemir V., Kalowa W., Tang B.K., Paterson A.D., Walker S.E., Endrenyi L., and Kashuba A.D. Pharmacogenetics 10 (2000) 373
3. Streetman D.S., Kashuba A.D., Bertino Jr. J.S., Kulawy R., Rocci Jr. M.L., and Nafziger A.N. Pharmacogenetics 11 (2001) 349
4. Streetman D.S., Bertino Jr. J.S., and Nafziger A.N. Pharmacogenetics 10 (2000) 187
5. Nordt S.P., and Clark R.F. J. Emerg. Med. 15 (1997) 357
6. Wandel C., Bocker R., Bohrer H., Browne A., Rugheimer E., and Martin E. Br. J. Anaesth. 73 (1994) 658
7. Rogers J.F., Rocci Jr. M.L., Haughey D.B., and Bertino Jr. J.S. Clin. Pharmacol. Ther. 73 (2003) 153
8. Zhu B., Ou-Yang D.S., Cheng Z.N., Huang S.L., and Zhou H.H. Acta. Pharmacol. Sin. 22 (2001) 634
9. Carrillo J.A., Ramos S.I., Agundez J.A., Martinez C., and Benitez J. Ther. Drug Monit. 20 (1998) 319
10. Thummel K.E., and Wilkinson G.R. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 389
11. Guengerich F.P. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 1
12. Tucker G.T., Houston J.B., and Huang S.M. Clin. Pharmacol. Ther. 70 (2001) 103
13. Sautou V., Chopineau J., Terrisse M.P., and Bastide P. J. Chromatogr. 571 (1991) 298
14. Ha H.R., Rentsch K.M., Kneer J., and Vonderschmitt D.J. Ther. Drug Monit. 15 (1993) 338
15. Lehmann B., and Boulieu R. J. Chromatogr. B Biomed. Appl. 674 (1995) 138
16. Lee T.C., and Charles B. Biomed. Chromatogr. 10 (1996) 65
17. Horst P.G.J., Foudraine N.A., Cuypers G., Dijk E.A., and Oldenhof N.J. J. Chromatogr. B 791 (2003) 389
18. Syracuse C.D., Kuhnert B.R., Kaine C.J., Santos A.C., and Finster M. J. Chromatogr. 380 (1986) 145
19. Sunzel M. J. Chromatogr. 491 (1989) 455
20. Kroon I.F., Langendijk P.N., and Goede P.N. J. Chromatogr. 491 (1989) 107
21. Yasui-Furukori N., Inoue Y., and Tateishi T. J. Chromatogr. B 811 (2004) 153
22. Martens J., and Banditt P. J. Chromatogr. B 692 (1997) 95
23. Eap C.B., Bouchoux G., Powell Golay K., and Baumann P. J. Chromatogr. B 802 (2004) 339
24. Marquet P., Baudin O., Gaulier J.M., Lacassie E., Dupuy J.L., Francois B., and Lachatre G. J. Chromatogr. B 734 (1999) 137
25. Sano T., Sato K., Kurihara R., Mizuno Y., Kojima T., Yamakawa Y., Yamada T., Ishii A., and Katsumata Y. Leg. Med. 3 (2001) 149
26. Lepper E.R., Hicks J.K., Verweij J., Zhai S., Figg W.D., and Sparreboom A. J. Chromatogr. B 806 (2004) 305
27. Muchohi S.N., Ward S.A., Preston L., Newton C.R., Edwards G., and Kokwaro G.O. J. Chromatogr. B 821 (2005) 1
28. Shiran M.R., Gregory A., Rostami-Hodjegan A., Tucker G.T., and Lennard M.S. J. Chromatogr. B 783 (2003) 303
29. Jabor V.A., Coelho E.B., Dos Santos N.A., Bonato P.S., and Lanchote V.L. J. Chromatogr. B 822 (2005) 27
30. U.S. Department of Health and Human Service Food and Drug Administration, Guidance for Industry Bioanalytical Method Validation, 2001, http://www.fda.gov./cder/guidance/4252fnl.pdf.
31. Kanazawa H., Okada A., Igarashi E., Higaki M., Miyabe T., Sano T., and Nishimura R. J. Chromatogr. A 1031 (2005) 213
32. Tateishi T., Watanabe M., Nakura H., Asoh M., Shirai H., Mizorogi Y., Kobayashi S., Thummel K.E., and Wilkinson G.R. Clin. Pharmacol. Ther. 69 (2001) 333
33. Lin Y.S., Lockwood G.F., Graham M.A., Brian W.R., Loi C.M., Dobrinska M.R., Shen D.D., Watkins P.B., Wilkinson G.R., Kharasch E.D., and Thummel K.E. Pharmacogenetics 11 (2001) 781